Large B-cell lymphomas (LBCLs) represent a frequent but clinically and morphologically heterogeneous group of tumors. Technological advances over the last 2 decades prompted the development of new classification schemas to sharpen diagnoses, dissect molecular heterogeneity, and identify rational treatment targets. Despite increased molecular understanding of these lymphomas, the clinical perspectives of patients largely remain unchanged. Recently finished comprehensive genomic studies discovered genetically defined LBCL subtypes that predict outcome, provide insight into lymphomagenesis, and suggest rational therapies with the hope of generating patient-tailored treatments with increased perspective for patients in greatest need. Here, we summarize notable examples of how high-throughput technologies aided in better molecular understanding of LBCLs and provided examples of rationally designed targeted treatments.

大的B细胞淋巴瘤（LBCL）代表了常见但在临床和形态上异质的肿瘤。在过去的20年中，技术的进步推动了新分类方案的发展，以加强诊断，剖析分子异质性并确定合理的治疗目标。尽管增加了对这些淋巴瘤的分子理解，但是患者的临床观点在很大程度上保持不变。最近完成的综合基因组研究发现了遗传定义的LBCL亚型，可预测结局，深入了解淋巴瘤的发生并提出合理的治疗方法，以期为最需要治疗的患者提供量身定制的治疗方法。这里，